155 related articles for article (PubMed ID: 33847939)
1. Detection of Complement Factor B Autoantibodies by ELISA.
Józsi M; Uzonyi B
Methods Mol Biol; 2021; 2227():141-145. PubMed ID: 33847939
[TBL] [Abstract][Full Text] [Related]
2. A humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors.
Paixão-Cavalcante D; Torreira E; Lindorfer MA; Rodriguez de Cordoba S; Morgan BP; Taylor RP; Llorca O; Harris CL
J Immunol; 2014 May; 192(10):4844-51. PubMed ID: 24729617
[TBL] [Abstract][Full Text] [Related]
3. Anti-factor B autoantibody in dense deposit disease.
Strobel S; Zimmering M; Papp K; Prechl J; Józsi M
Mol Immunol; 2010 Apr; 47(7-8):1476-83. PubMed ID: 20193965
[TBL] [Abstract][Full Text] [Related]
4. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.
Marinozzi MC; Chauvet S; Le Quintrec M; Mignotet M; Petitprez F; Legendre C; Cailliez M; Deschenes G; Fischbach M; Karras A; Nobili F; Pietrement C; Dragon-Durey MA; Fakhouri F; Roumenina LT; Fremeaux-Bacchi V
Kidney Int; 2017 Nov; 92(5):1232-1241. PubMed ID: 28712854
[TBL] [Abstract][Full Text] [Related]
5. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.
Bettoni S; Bresin E; Remuzzi G; Noris M; Donadelli R
J Biol Chem; 2016 Apr; 291(15):8214-30. PubMed ID: 26903516
[TBL] [Abstract][Full Text] [Related]
6. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
Front Immunol; 2018; 9():2329. PubMed ID: 30487789
[TBL] [Abstract][Full Text] [Related]
7. Autoantibody to complement neoantigens in membranoproliferative glomerulonephritis.
Strife CF; Prada AL; Clardy CW; Jackson E; Forristal J
J Pediatr; 1990 May; 116(5):S98-102. PubMed ID: 2329415
[TBL] [Abstract][Full Text] [Related]
8. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
Michels MAHM; van de Kar NCAJ; Okrój M; Blom AM; van Kraaij SAW; Volokhina EB; van den Heuvel LPWJ
Front Immunol; 2018; 9():612. PubMed ID: 29670616
[TBL] [Abstract][Full Text] [Related]
9. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
[TBL] [Abstract][Full Text] [Related]
10. C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.
Zhang Y; Meyer NC; Fervenza FC; Lau W; Keenan A; Cara-Fuentes G; Shao D; Akber A; Fremeaux-Bacchi V; Sethi S; Nester CM; Smith RJH
Am J Kidney Dis; 2017 Dec; 70(6):834-843. PubMed ID: 28838767
[TBL] [Abstract][Full Text] [Related]
11. Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations.
Corvillo F; Okrój M; Nozal P; Melgosa M; Sánchez-Corral P; López-Trascasa M
Front Immunol; 2019; 10():886. PubMed ID: 31068950
[TBL] [Abstract][Full Text] [Related]
12. Functional Hemolytic Test for Complement Alternative Pathway Convertase Activity.
Michels MAHM; van de Kar NCAJ; Volokhina EB; van den Heuvel BLPWJ
Methods Mol Biol; 2021; 2227():83-96. PubMed ID: 33847933
[TBL] [Abstract][Full Text] [Related]
13. The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb).
Bexborn F; Andersson PO; Chen H; Nilsson B; Ekdahl KN
Mol Immunol; 2008 Apr; 45(8):2370-9. PubMed ID: 18096230
[TBL] [Abstract][Full Text] [Related]
14. Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme.
Halbwachs L; Leveillé M; Lesavre P; Wattel S; Leibowitch J
J Clin Invest; 1980 Jun; 65(6):1249-56. PubMed ID: 6902727
[TBL] [Abstract][Full Text] [Related]
15. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB
Front Immunol; 2021; 12():715704. PubMed ID: 34456924
[TBL] [Abstract][Full Text] [Related]
16. Anti-Factor B Antibodies and Acute Postinfectious GN in Children.
Chauvet S; Berthaud R; Devriese M; Mignotet M; Vieira Martins P; Robe-Rybkine T; Miteva MA; Gyulkhandanyan A; Ryckewaert A; Louillet F; Merieau E; Mestrallet G; Rousset-Rouvière C; Thervet E; Hogan J; Ulinski T; Villoutreix BO; Roumenina L; Boyer O; Frémeaux-Bacchi V
J Am Soc Nephrol; 2020 Apr; 31(4):829-840. PubMed ID: 32034108
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of C3 nephritic factor of alternative complement pathway by an enzyme-linked immunosorbent assay.
Seino J; Fukuda K; Kinoshita Y; Sudo K; Horigome I; Sato H; Saito T; Furuyama T; Yoshinaga K
J Immunol Methods; 1987 Dec; 105(1):119-25. PubMed ID: 3680963
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
Noris M; Donadelli R; Remuzzi G
Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
[TBL] [Abstract][Full Text] [Related]
19. Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome.
Józsi M; Reuter S; Nozal P; López-Trascasa M; Sánchez-Corral P; Prohászka Z; Uzonyi B
Immunol Lett; 2014 Aug; 160(2):163-71. PubMed ID: 24491679
[TBL] [Abstract][Full Text] [Related]
20. [Progress in the knowledge of complement. II. Nephritic factors].
Leibowitch J; Lesavre P
Nouv Presse Med; 1979 Jul; 8(30):2447-8. PubMed ID: 493036
[No Abstract] [Full Text] [Related]
[Next] [New Search]
